NPCE – neuropace, inc. (US:NASDAQ)
Stock Stats
News
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at UBS Group AG from $18.00 to $22.00. They now have a "buy" rating on the stock.
NeuroPace (NASDAQ:NPCE) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.
NeuroPace (NASDAQ:NPCE) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Form 4 NeuroPace Inc For: Dec 19 Filed by: LACOB JOSEPH
Form 4 NeuroPace Inc For: Dec 19 Filed by: Kumar Rakhi
Form 4 NeuroPace Inc For: Dec 19 Filed by: Geiger Uri
Form 4 NeuroPace Inc For: Dec 19 Filed by: Fischer Frank M
Form 144 NeuroPace Inc Filed by: Morrell Martha
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.